Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

VGASW vs ABSI: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ABSI Wins Head-to-Head Institutional Verdict (3–1 across 6 Pillars · 8–0 Matrix Metrics)

ABSI Overall Winner 6-Pillar Tally: VGASW 1 – 3 ABSI (2 Tie) Matrix Metrics: VGASW 0 – 8 ABSI

As of Nov 20, 2026, Absci Corporation (ABSI) is the stronger overall head-to-head candidate over VGASW (VGASW) in the Tradestie Institutional Equity Comparison Engine, winning 8–0 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). VGASW carries a Unified Composite Score of 49.2/100 (HOLD) at $0.01 (N/M Forward P/E, N/A operating margin), whereas ABSI carries 61.0/100 (BUY) at $7.51 (N/M Forward P/E, -9108.3% operating margin).

  • Technical & Structure Timing Caution: VGASW is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.8); meanwhile ABSI is in a Breakdown options structure phase (RSI 39.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About VGASW vs ABSI
VGASW US Equity
VGASW
Institutional Equity
$0.01
+16.84% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.48β · 257% Vol
Unified Composite Score
49.2 / 100 HOLD
Tech 50.0 Fund 52.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -12.7%), weak momentum, RSI 38
RSI-14: 37.8 · SMA20: $0.02 · SMA50: $0.03
ABSI NASDAQ Head-to-Head Winner
Absci Corporation Common Stock
Services-Commercial Physical & Biological Research
$7.51
-7.97% 1D
Market Cap $1.4B
TTM Revenue $1.5M
Forward P/E N/M
Beta / 30D Vol 3.18β · 122% Vol
Unified Composite Score
61.0 / 100 BUY
Tech 75.0 Fund 63.0 Flow 57.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 39
RSI-14: 39.2 · SMA20: $9.61 · SMA50: $9.58

6-Pillar Scorecard Institutional Category Breakdown (VGASW 1 – 3 ABSI)

Columns: Metric · VGASW · ABSI
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale ABSI
Revenue Growth (YoY) N/A -19.6%
Earnings Growth (YoY) N/A +0.0%
TTM Revenue (USD) N/A $1.5M
Market Cap N/A $1.4B
3. Profitability & Quality ABSI
Gross Margin N/A N/A
Operating Margin N/A -9108.3%
Net Profit Margin N/A 0.0%
Return on Equity (ROE) N/A -58.6%
4. Balance Sheet & Cash Flow ABSI
Cash Generation (TTM) N/A -$112M
Cash Flow Margin N/A N/A
Net Cash / Leverage N/A ROE $10M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning VGASW
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) 108.5% (7th %ile)
Put/Call OI Skew N/A 0.80x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: VGASW (0) vs ABSI (8)
Institutional Metric VGASW ABSI Criterion Row Edge
Market Capitalization
Scale
N/A $1.4B Larger Scale ABSI
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
N/A -19.6% Higher Growth ABSI
Operating Margin (TTM)
Profitability
N/A -9108.3% Higher Margin ABSI
Net Profit Margin
Profitability
N/A 0.0% Higher Margin ABSI
Return on Equity (ROE)
Capital Efficiency
N/A -58.6% Higher ROE ABSI
52-Week Range Position
Momentum
3% ($0–$0) 51% ($2–$13) Stronger Trend ABSI
Beta / 30D Volatility
Risk Regime
0.48β · 257% Vol 3.18β · 122% Vol Lower Realized Risk ABSI
Unified Institutional Score
Composite Signal
49.2 / 100 (HOLD) 61.0 / 100 (BUY) Higher Composite ABSI
Trailing 12M Revenue (USD)
Operating Scale
N/A $1.5M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) -$112M ($10M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon VGASW +5.23 pp
VGASW: -20.71% · ABSI: -25.94%
3M Horizon ABSI +21.38 pp
VGASW: -56.3% · ABSI: -34.92%
6M Horizon ABSI +216.36 pp
VGASW: -55.6% · ABSI: +160.76%
1Y Horizon ABSI +250.26 pp
VGASW: -87.67% · ABSI: +162.59%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on VGASW vs ABSI. Trailing 12-month operating profitability (VGASW N/A vs ABSI -9108.3%) and valuation multiples (VGASW N/M vs ABSI N/M Forward P/E) are benchmarked directly in Pillar 4 below.

VGASW ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
ABSI ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.5M
Gross MarginN/A
Op. Margin-9108.3%
ROE / Fwd P/E-58.6% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
VGASW UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact VGASW Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ABSI BREAKDOWN
101d in phase · OBV DISTRIBUTION
Current IV 108.5%
IV Percentile 7th %ile
Put/Call OI Skew 0.80x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact ABSI Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
VGASW Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ABSI Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.4B market capitalization and -9108.3% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ VGASW vs ABSI Key Questions & Quantitative Answers

As of Nov 20, 2026, Absci Corporation (ABSI) is the stronger overall head-to-head candidate over VGASW (VGASW) in the Tradestie Institutional Equity Comparison Engine, winning 8–0 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). VGASW carries a Unified Composite Score of 49.2/100 (HOLD) at $0.01 (N/M Forward P/E, N/A operating margin), whereas ABSI carries 61.0/100 (BUY) at $7.51 (N/M Forward P/E, -9108.3% operating margin). Technical & Structure Timing Caution: VGASW is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.8); meanwhile ABSI is in a Breakdown options structure phase (RSI 39.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ABSI leads the Growth & Scale pillar: VGASW posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with ABSI at -19.6% YoY revenue growth and +0.0% YoY earnings growth on $1.5M TTM revenue (N/A gross margin, -9108.3% operating margin). On trailing 12-month operating scale, VGASW generates N/A in USD-normalized revenue versus $1.5M for ABSI. In operating R&D and SG&A reinvestment, VGASW deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ABSI.

VGASW and ABSI trade at balanced relative valuation multiples. VGASW trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas ABSI trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VGASW (N/A ROE) versus ABSI (-58.6% ROE) capital efficiency.

In options market volatility and institutional positioning, VGASW carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.48β · 257% Vol realized risk). By comparison, ABSI carries 108.5% implied volatility (7th %ile, Compressed (<25th %ile)), a 0.80x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (3.18β · 122% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.